Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Oleksandr Voitko"'
Autor:
Oleksandr Voitko, Jonathan W. Goldman, Niels Reinmuth, György Losonczy, Katsuyuki Hotta, P. Thiyagarajah, J.H. Ji, Luis Paz-Ares, Maximilian Hochmair, Mustafa Ozguroglu, Y. Chen, Nikolay Conev, Helen Broadhurst, Marina Chiara Garassino, D. Trukhin, Libor Havel, Francesco Verderame, Galina Statsenko, N. Byrne, Mikhail Dvorkin
Publikováno v:
Web of Science
9068 Background: In the Phase 3, randomized, open-label CASPIAN study, first-line durvalumab (D) added to etoposide plus either cisplatin or carboplatin (EP) significantly improved OS vs EP alone (HR 0.73 [95% CI 0.59–0.91]; p = 0.0047) in pts with
Autor:
Maximilian Hochmair, Niels Reinmuth, D. Trukhin, Oleksandr Voitko, N. Byrne, Jonathan W. Goldman, Igor Bondarenko, Luis Paz-Ares, Haiyi Jiang, Mikhail Dvorkin, Katsuyuki Hotta, Jon Armstrong, Galina Statsenko, Mustafa Ozguroglu, Y. Chen, Jun Ho Ji, Libor Havel, Francesco Verderame, A. Poltoratskiy
Publikováno v:
Journal of Clinical Oncology. 38:9002-9002
9002 Background: CASPIAN is an open-label, Phase 3 study of durvalumab (D) ± tremelimumab (T) + etoposide and either cisplatin or carboplatin (EP) for pts with 1L ES-SCLC. At the planned interim analysis (data cutoff Mar 11, 2019; 63% maturity), D +